MSBase Registry research articles published in peer-reviewed journals

2021

Determinants of therapeutic lag in multiple sclerosis

Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Debouverie, M. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Edan, G. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Grammond, P. Ciron, J. Ruet, A. Ozakbas, S. De Seze, J. Louapre, C. Zephir, H. Sá, MJ. Sola, P. Ferraro, D. Labauge, P. Defer, G. Bergamaschi, R. Lebrun-Frenay, C. Boz, C. Cartechini, E. Moreau, T. Laplaud, D. Lechner-Scott, J. Grand'Maison, F. Gerlach, O. Terzi, M. Granella, F. Alroughani, R. Iuliano, G. Van Pesch, V. Van Wijmeersch, B. Spitaleri, D. Soysal, A. Berger, E. Prevost, J. Aguera-Morales, E. McCombe, P. Castillo Triviño, T. Clavelou, P. Pelletier, J. Turkoglu, R. Stankoff, B. Gout, O. Thouvenot, E. Heinzlef, O. Sidhom, Y. Gouider, R. Csepany, T. Bourre, B. Al Khedr, A. Casez, O. Cabre, P. Montcuquet, A. Wahab, A. Camdessanche, JP. Maurousset, A. Patry, I. Hankiewicz, K. Pottier, C. Maubeuge, N. Labeyrie, C. Nifle, C. Coles, A. Malpas, CB. Vukusic, S. Butzkueven, H. Kalincik, T. Mult Scler. doi: 10.1177/1352458520981300. [Online ahead of print – Jan 2021]. PMID: 33423618

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Kalincik, T. Diouf, I. Sharmin, S. Malpas, C. Spelman, T. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Jokubaitis, V. van der Walt, A. Grand'Maison, F. Sola, P. Ferraro, D. Shaygannejad, V. Alroughani, R. Hupperts, R. Terzi, M. Boz, C. Lechner-Scott, J. Pucci, E. Van Pesch, V. Granella, F. Bergamaschi, R. Spitaleri, D. Slee, M. Vucic, S. Ampapa, R. McCombe, P. Ramo-Tello, C. Prevost, J. Olascoaga, J. Cristiano, E. Barnett, M. Saladino, ML. Sanchez-Menoyo, JL. Hodgkinson, S. Rozsa, C. Hughes, S. Moore, F. Shaw, C. Butler, E. Skibina, O. Gray, O. Kermode, A. Csepany, T. Singhal, B. Shuey, N. Piroska, I. Taylor, B. Simo, M. Sirbu, CA. Sas, A. Butzkueven, H. MSBase Study group. Neurology. 10.1212/WNL.0000000000011242. doi: 10.1212/WNL.0000000000011242. [Online ahead of print - Dec 2020].PMID: 33372028

2020

Treatment response score to glatiramer acetate or interferon beta-1a. Bovis, F. Kalincik, T. Lublin, F. Cutter, G. Malpas, C. Horakova, D. Havrdova, EK. Trojano, M. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Izquierdo, G. Eichau, S. Patti, F. Terzi, M. Grammond, P. Bergamaschi, R. Sola, P. Ferraro, D. Ozakbas, S. Iuliano, G. Boz, C. Hupperts, R. Grand'Maison, F. Oreja-Guevara, C. van Pesch, V. Cartechini, E. Petersen, T. Altintas, A. Soysal, A. Ramo-Tello, C. McCombe, P. Turkoglu, R. Butzkueven, H. Wolinsky, JS. Solaro, C. Sormani, MP. Neurologydoi: 10.1212/WNL.0000000000010991 [Online ahead of print – Oct 2020].

Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Onofrj, M. Lugaresi, A. Prat, A. Girard, M. Grammond, P. Sola, P. Ferraro, D. Ozakbas, S. Bergamaschi, R. Sá, MJ. Cartechini, E. Boz, C. Granella, F. Hupperts, R. Terzi, M. Lechner-Scott, J. Spitaleri, D. Van Pesch, V. Soysal, A. Olascoaga, J. Prevost, J. Aguera-Morales, E. Slee, M. Csepany, T. Turkoglu, R. Sidhom, Y. Gouider, R. Van Wijmeersch, B. McCombe, P. Macdonell, R. Coles, A. Malpas, CB. Butzkueven, H. Vukusic, S. Kalincik, T.; MSBase; OFSEP investigators. Brain. (Sept 2020) 143(9): 2742-2756. 10.1093/brain/awaa231

Association of Pregnancy With the Onset of Clinically Isolated Syndrome. Nguyen, A. Vodehnalova, K. KalinciK, T. Signori, A. Havrdova, E.K. Lechner-Scott, J. Skibina, O.G. Eastaugh, A. Taylor, L. Baker, J. McGuinn, N. Rath, L. Maltby, V. Sormani, MP. Butzkueven, H. Van der Walt, A. Horakova, D. Jokubaitis, V.G. JAMA Neurol. doi: 10.1001/jamaneurol.2020.3324. [Online ahead of print – Sept 2020].

Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. Lizak, N.  Malpas,, C.B. Sharmin, S. Havrdova, E.K.  Horakova, D.  Izquierdo, G. ,  Eichau, S. Lugaresi, A. Duquette, P. Girard, M. Prat, A. Larochelle, C. Trojano, M. Grand'Maison, F. Grammond, P.  Sola, P. Ferraro, D.  Hupperts, R. Bergamaschi, R. Boz, C. Van Pesch, V. Spitaleri, D. Terzi, M.  Kalincik, T.  MSBase Study Group JAMA Neurol. https://pubmed.ncbi.nlm.nih.gov/32716480/ [Online ahead of print – Jul 2020].

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Kunchok, A. Lechner-Scott, J. Granella, F. Trojano, M. Alroughani, R. Sola, P. Ferraro, D. Lugaresi, A. Onofrj, M. Ozakbas, S. Izquierdo, G. Grammond, P. Luis Sanchez-Menoyo, J. Van Wijmeersch, B. Boz, C. Pucci, E. McCombe, P. Grand'Maison, F. Spitaleri, D. Vucic, S. Hupperts, R. Jokubaitis, V. Sormani, MP. Butzkueven, H. Kalincik, T.; MSBase Study Group. Mult Scler. https://doi: 10.1177/1352458520936823. [Online ahead of print – Jul 2020].

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Le, M. Malpas, C. Sharmin, S. Horáková, D. Havrdova, E. Trojano, M. Izquierdo, G. Eichau, S. Ozakbas, S. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Larochelle, C. Alroughani, R. Bergamaschi, R. Sola, P. Ferraro, D. Grammond, P. Grand' Maison, F. Terzi, M. Boz, C. Hupperts, R. Butzkueven, H. Pucci, E. Granella, F. Van Pesch, V. Soysal, A. Yamout, BI. Lechner-Scott, J. Spitaleri, D. Ampapa, R. Turkoglu, R. Iuliano, G. Ramo-Tello, C. Sanchez-Menoyo, JL. Sidhom, Y. Gouider, R. Shaygannejad, V. Prevost, J. Altintas, A. Fragoso, YD. McCombe, PA. Petersen, T. Slee, M. Barnett, MH. Vucic, S. Van Der Walt, A. Kalincik, T. Mult Sclerhttps://doi/10.1177/1352458520926955 [Online ahead of print – Jun 2020].

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Lizak, N. Hodgkinson, S. Butler, E. Lechner-Scott, J. Slee, M. McCombe, PA. Shaw, C. Skibina, O. Vucic, S. Shuey, N. Barnett, MH. Parratt, J. Butzkueven, H. Jack, D. Fabris, J. Kalincik, T. Mult Scler. https://doi.org/10.1177/1352458520921087 [Online ahead of print – Jun 2020].

Early clinical markers of aggressive multiple sclerosis. Malpas, CB. Manouchehrinia, A. Sharmin, S. Roos, I. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Eichau, S. Bergamaschi, R. Sola, P. Ferraro, D. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Grand'Maison, F. Ozakbas, S. Van Pesch, V. Granella, F. Hupperts, R. Pucci, E. Boz, C. Sidhom, Y. Gouider, R. Spitaleri, D. Soysal, A. Petersen, T. Verheul, F. Karabudak, R. Turkoglu, R. Ramo-Tello, C. Terzi, M. Cristiano, E. Slee, M. McCombe, P. Macdonell, R. Fragoso, Y. Olascoaga, J. Altintas, A. Olsson, T. Butzkueven, H. Hillert, J. Kalincik, Brain. (May 2020) 143(5): 1400-1413. http://doi.org/10.1093/brain/awaa081 

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observation cohort study. He, A. Merkel, B. Brown, JWL. Zhovits Ryerson, L. Kister, I. Malpas, CB. Sharmin, S. Horakova, D. Kubala Havrdova, E. Spelman, T. Izquierdo, G. Eichau, S. Trojano, M. Lugaresi, A. Hupperts, R. Sola, P. Ferraro, D. Lycke, J. Grand'Maison, F. Prat, A. Girard, M. Duquette, P. Larochelle, C. Svenningsson, A. Petersen, T. Grammond, P. Granella, F. Van Pesch, V. Bergamaschi, R. McGuigan, C. Coles, A. Hillert, J. Piehl, F. Butzkueven, H. Kalincik, T; MSBase study group. Lancet Neurol. (Apr. 2020) 19(4):307-316. https://doi.org/10.1016/S1474-4422(20)30067-3.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Kunchok, A. Malpas, C. Nytrova, P. Havrdova, EK. Alroughani, R. Terzi, M. Yamout, B. Hor, JY. Karabudak, R. Boz, C. Ozakbas, S. Olascoaga, J. Simo, M. Granella, F. Patti, F. McCombe, P. Csepany, T. Singhal, B. Bergamaschi, R. Fragoso, Y. Al-Harbi, T. Turkoglu, R. Lechner-Scott, J. Laureys, G. Oreja-Guevara, C. Pucci, E. Sola, P. Ferraro, D. Altintas, A. Soysal, A. Vucic, S. Grand'Maison, F. Izquierdo, G. Eichau, S. Lugaresi, A. Onofrj, M. Trojano, M. Marriott, M. Butzkueven, H. Kister, I. Kalincik, T. Mult Scler Relat Disord. http://dx.doi.org/10.1016/j.msard.2019.101868 [Epub ahead of print].

Risk of secondary progressive multiple sclerosis: A longitudinal study. Fambiatos, A. Jokubaitis, V. Horakova, D. Kubala Havrdova, E. Trojano, M. Prat, A. Girard, M. Duquette, P. Lugaresi, A. Izquierdo, G. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Alroughani, R. Terzi, M. Hupperts, R. Boz, C. Lechner-Scott, J. Pucci, E. Bergamaschi, R. Van Pesch, V. Ozakbas, S. Granella, F. Turkoglu, R. Iuliano, G. Spitaleri, D. McCombe, P. Solaro, C. Slee, M. Ampapa, R. Soysal, A. Petersen, T. Sanchez-Menoyo, JL. Verheu, F. Prevost, J. Sidhom, Y. Van Wijmeersch, B. Vucic, S. Cristiano, E. Saladino, ML. Deri, N. Barnett, M. Olascoaga, J. Moore, F. Skibina, O. Gray, O. Fragoso, Y. Yamout, B. Shaw, C. Singhal, B. Shuey, N. Hodgkinson, S. Altintas, A. Al-Harbi, T. Csepany, T. Taylor, B. Hughes, J. Jun, JK. van der Walt, A. Spelman, T. Butzkueven, H. Kalincik, T. Mult Scler. (Jan 2020) 26(1): 79-90 https://doi.org/10.1177/1352458519868990

2019

The MSBase Registry: Informing Clinical Practice. Kalincik, T. Butzkueven, H. Mult Scler. (Dec 2019) 25(14): 1828-1834 https://doi.org/10.1177/1352458519848965

Comparison of fingolimod, dimethyl fumarate and teriflunomide for Multiple Sclerosis. Kalincik, T. Kubala Havrdova, E. Horakova, D. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Grammond, P. Onofrj, M. Lugaresi, A. Ozakbas, S. Kappos, L. Kuhle, J. Terzi, M. Lechner-Scott, J. Boz, C. Grand'Maison, F. Prevost, J. Sola, P. Ferraro, D. Granella, F. Trojano, M, Bergamaschi, R. Pucci, E. Turkoglu, R. McCombe, P.A. Pesch, V.V. Van Wijmeersch, B. Solaro, C. Ramo-Tello, C. Slee, M. Alroughani, R. Yamout, B. Shaygannejad, V. Spitaleri, D. Sánchez-Menoyo, J.L. Ampapa, R. Hodgkinson, S. Karabudak, R. Butler, E. Vucic, S. Jokubaitis, V. Spelman, T. Butzkueven, H.   J Neurol. Neurosurg Psychiatry(Apr 2019) 90(4): 458-468.  http://dx.doi.org/10.1136/jnnp-2018-319831 

Incidence of pregnancy and disease-modifying therapy exposure trends in women with Multiple Sclerosis: A contemporary cohort study. Nguyen, A.L. Havrdova, E.K. Horakova, D. Izquierdo, G. Kalincik, T. van der Walt, A. Terzi, M. Alroughani, R. Duquette, P. Girard, M. Prat, A. Boz, C. Sola, P. Ferraro, D. Lugaresi, A. Lechner-Scott, J. Barnett, M. Grand'Maison, F. Grammond, P. Ramo-Tello, C. Turkoglu, R. McCombe, P. Pucci, E. Trojano, M. Granella, F. Spitaler, D. Van Pesch, V. Soysal, A. Oreja-Guevara, C. Verheul, F. Vucic, S. Hodgkinson, S. Slee, M. Ampapa, R. Prevost, J. Menoyo, J.L.S. Skibina, O. Solaro, C. Olascoaga, J. Shaw, C. Madsen, K.G. Naidoo, K. Hyde, R. Butzkueven, H. Jokubaitis, V.; MSBase Study Group.  Mult Scler Relat Disord. (Feb 2019) 28:235-243.   http://dx.doi.org/10.1016/j.msard.2019.01.003 

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Lorscheider, J., J. Kuhle, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, R. Hupperts, P. Duquette, M. Girard, A. Prat, F. Grand’Maison, P. Grammond, P. Sola, D. Ferraro, M. Trojano, C. Ramo-Tello, J. Lechner-Scott, E. Pucci, C. Solaro, M. Slee, V. van Pesch, J.L.S. Menoyo, A van der Walt, H. Butzkueven, L. Kappos, T. Kalincik, on behalf of the MSBase Study Group. Eur J Neurol. (Feb 2019) 26(2): 363-370.   http://dx.doi.org/10.1111/ene.13824. 

Association of Initial Disease-Modifying Therapy with later conversion to Secondary Progressive Multiple Sclerosis. Brown, J.W.L. Coles, A. Horakova, D, Havrdova, E. Izquierdo, G. Prat, A. Girard, M. Duquette, P. Trojano, M. Lugaresi, A. Bergamaschi, R. Grammond, P. Alroughani, R. Hupperts, R. McCombe, P. Van Pesch, V. Sola, P. Ferraro, D. Grand'Maison, F. Terzi, M. Lechner-Scott, J. Flechter, S. Slee, M. Shaygannejad, V. Pucci, E. Granella, F. Jokubaitis, V. Willis, M. Rice, C. Scolding, N. Wilkins, A. Pearson, O.R. Ziemssen, T. Hutchinson, M. Harding, K. Jones, J. McGuigan, C. Butzkueven, H. Kalincik, T. Robertson, N; MSBase Study Group. JAMA (Jan 2019) 15;321(2): 175-187 http://dx.doi.org/10.1001/jama.2018.20588

2018

Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis. Hughes, J., V. Jokubaitis, A. Lugaresi, R. Hupperts, G. Izquierdo, A. Prat, M. Girard, P. Duquette, F. Grand’Maison, P. Grammond, P. Sola, D. Ferraro, C. Ramo-Tello, M. Trojano, M. Slee, V. Shaygannejad, C. Boz, J. Lechner-Scott, V. Van Pesch, E. Pucci, C. Solaro, F. Verheul, M. Terzi, F. Granella, D. Spitaleri, R. Alroughani, J. K. Jun, A. Fambiatos, A. Van der Walt, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. JAMA Neurol. (Nov 2018) 1;75(11):1407-1415. http://dx.doi.org/10.1001/jamaneurol.2018.2109 

Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. Min, M., T. Spelman, A. Lugaresi, C. Boz, D. Spitaleri, E. Pucci, F. Grand’Maison, F. Granella, G. Izquierdo, H. Butzkueven, J. L. Sanchez-Menoyo, M. Barnett, M. Girard, M. Trojano, P. Grammond, P. Duquette, P. Sola, R. Alroughani, R. Hupperts, S. Vucic, T. Kalincik, V. Van-Pesch and J. Lechner-Scott Mult Scler. (Oct 2018) 24(12): 1569-1577 http://dx.doi.org/10.1177/1352458518798147 

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Kalincik, T., V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. Butler, M. Slee, A. Kermode, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueve, on behalf of the MSBase Study Group. Mult. Scler. (Oct 2018) 24(12):1617-1626. http://dx.doi.org/10.1177/1352458517728812

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Kister, I., T. Spelman, F. Patti, P. Duquette, M. Trojano, G. Izquierdo, A. Lugaresi, P. Grammond, P. Sola, D. Ferraro, F. Grand’Maison, R. Alroughani, M. Terzi, C. Boz, R. Hupperts, J. Lechner-Scott, L. Kappos, E. Pucci, S. Hodgkinson, C. Solaro, H. Butzkueven. J Neurol Sci (Aug 2018) 391: 72-76. http://dx.doi.org/10.1016/j.jns.2018.06.001

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Signori, A., G. Izquierdo, A. Lugaresi, R. Hupperts, F. Grand’Maison, P. Sola, D. Horakova, E. Havrdova, A. Prat, M. Girard, P. Duquette, C. Boz, P. Grammond, M. Terzi, B. Singhal, R. Alroughani, T. Petersen, C. Ramo, C. Oreja-Guevara, D. Spitaleri, V. Shaygannejad, H. Butzkueven, T. Kalincik, V. Jokubaitis, M. Slee, R. Fernández Bolaños , J. L. Sanchez-Menoyo, E. Pucci, F. Granella, J. Lechner-Scott, G. Iuliano, S. Hughes, R. Bergamaschi, B. Taylor, F. Verheul, M. Edite Rio, M.P. Amato, S.A. Sajedi, N. Majdinasab, V. Van Pesch, M.P. Sormani, M. Trojano. Mult Scler. (Apr 2018) 24(5): 642-652.  http://dx.doi.org/10.1177/1352458517703800

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Fragoso, Y. D., T. Spelman, C. Boz, R. Alroughani, A. Lugaresi, S. Vucic, H. Butzkueven, M. Terzi, E. Havrdova, D. Horakova, F. Granella, J. Olascoaga, J. L. Sanchez-Menoyo, E. Pucci, M. Barnett, J. B. B. Brooks, J. Haartsen, on behalf of the MSBase Lymphopenia and Efficacy of Fingolimod Sub-Study Investigators. Mult Scler Relat Disord. (Jan 2018) 19: 105-108. http://dx.doi.org/10.1016/j.msard.2017.11.018

2017

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Kalincik, T, A. Manouchehrinia, L. Sobisek, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, R. Hupperts, F. Grand’Maison, E. Pucci, C. Boz, R. Alroughani, V. Van Pesch, J. Lechner-Scott, M. Terzi, R. Bergamaschi, G. Iuliano, F, Granella, D. Spitaleri, V. Shaygannejad, C. Oreja-Guevara, M. Slee, R. Ampapa, F. Verheul, P. McCombe, J. Olascoaga, M. P. Amato, S. Vucic, S. Hodgkinson, C. Ramo-Tello, S. Flechter, E. Cristiano, C. Rozsa, F. Moore, J. L. Sanchez-Menoyo, M. L. Saladino, M. Barnett, J. Hillert, H. Butzkueven, on behalf of the MSBase Study Group. Brain. (Sep 2017) 140(9): 2426-2443. http://dx.doi.org/10.1093/brain/awx185

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Lorscheider, J., V. G. Jokubaitis, T. Spelman, G. Izquierdo, A. Lugaresi, E. Havrdova, D. Horakova, M. Trojano, P. Duquette, M. Girard, A. Prat, F. Grand'Maison, P. Grammond, E. Pucci, C. Boz, P. Sola, D. Ferraro, D. Spitaleri, J. Lechner-Scott, M. Terzi, V. Van Pesch, G. Iuliano, R. Bergamaschi, C. Ramo-Tello, F. Granella, C. Oreja-Guevara, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. Neurology. (Sep 2017) 89(10):1050-1059. http://dx.doi.org/10.1212/WNL.0000000000004330

Quantifying risk of early relapse in patients with demyelinating events: Prediction in clinical practice. Spelman, T., C. Meyniel, J.L. Rojas, A. Lugaresi, G. Izquierdo, F. Grand’Maison, C. Boz, R. Alroughani, E. Havrdova, D. Horakova, G. Iuliano, P. Duquette, M. Terzi, P. Grammond, R. Hupperts, J. Lechner-Scott, C. Oreja-Guevara, E. Pucci, F. Verheul, M. Fiol, V. Van Pesch, E. Cristiano, T. Petersen, F. Moore, T. Kalincik, V. Jokubaitis, M. Trojano, H. Butzkueven on behalf of the MSBasis (an MSBase Substudy) Investigators. Mult Scler. (Sep 2017) 23(10): 1346-1357.  http://dx.doi.org/10.1177/1352458516679893

Incidence and prevalence of NMOSD in Australia and New Zealand. Bukhari, W., K. M. Prain, P. Waters, M. Woodhall, C. M. O’Gorman, L. Clarke, R. A. Silvestrini, C. S. Bundell, D. Abernethy, S. Bhuta, S. Blum, M. Boggild, K. Boundy, B. J. Brew, M. Brown, W. J. Brownlee, H. Butzkueven, W. M. Carroll, C. Chen, A. Coulthard, R. C. Dale, C. Das, K. Dear, M. J. Fabis-Pedrini, D. Fulcher, D. Gillis, S. Hawke, R. Heard, A. P. D. Henderson, S. Heshmat, S. Hodgkinson, S. Jimenez-Sanchez, T. Killpatrick, J. King, C. Kneebone, A. J. Kornberg, J. Lechner-Scott, M. W. Lin, C. Lynch, R. Macdonell, D. F. Mason, P. A. McCombe, M. P. Pender, J. A. Pereira, J. D. Pollard, S. W. Reddel, C. Shaw, J. Spies, J. Stankovich, I. Sutton, S. Vucic, M. Walsh, R. C. Wong, E. M. Yiu, M. H. Barnett, A. G. Kermode, M. P. Marriott, J. D. E. Parratt, M. Slee, B. V. Taylor, E. Willoughby, R. J. Wilson, A. Vincent, S. A. Broadly. J Neurosurg Psychiatry. (Aug 2017) 88(8):632-638. http://dx.doi.org/10.1136/jnnp-2016-314839 

Prognostic indicators in pediatric clinically isolated syndrome. Iaffaldano, P., M. Simone, G. Lucisano, A. Ghezzi, G. Coniglio, V. Brescia Morra, F. Patti, A. Lugaresi, G. Izquierdo, R. Bergamaschi, J. A. Cabrera-Gomez, C. Pozzilli, E. Millefiorini, R. Alroughani, C. Boz, E. Pucci, G. B. Zimatore, P. Sola, G. Lus, D. Maimone, C. Avolio, E. Cocco, S.A. Sajedi, G. Costantino, P. Duquette, V. Shaygannejad, T. Petersen, R. Fernández Bolaños, D. Paolicelli, C. Tortorella, T. Spelman, L. Margari, M.P. Amato, G. Comi, H. Butzkueven, M. Trojano, on behalf of the Italian iMedWeb Registry and the MSBase Registry. Ann Neurol. (May 2017) 81(5):729-739. http://dx.doi.org/10.1002/ana.24938

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Kalincik, T., J.W.L. Brown, N. Robertson, M. Willis, N. Scolding, C.M. Rice, A. Wilkins, O. Pearson, T. Ziemssen, M. Hutchinson, C. McGuigan, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, R. Alroughani, E. Pucci, P. Sola, R. Hupperts, J. Lechner-Scott, M. Terzi, V. Van Pesch, C. Rozsa, F. Grand’Maison, C. Boz, F. Granella, M. Slee, D. Spitaleri, J. Olascoaga, R. Bergamaschi, F. Verheul, S. Vucic, P. McCombe, S. Hodgkinson, J.L. Sanchez-Menoyo, R. Ampapa, M. Simo, T. Csepany, C. Ramo, E. Cristiano, M. Barnett, H. Butzkueven, A. Coles on behalf of the MSBase Study Group. Lancet Neurol. (Apr 2017) 16(4):271-281. http://dx.doi.org/10.1016/S1474-4422(17)30007-8

Data quality evaluation for observational multiple sclerosis registries. Kalincik, T., J. Kuhle, E. Pucci, J. I. Rojas, M. Tsolaki, C. A. Sirbu, M. Slee, H. Butzkueven, on behalf of the MSBase Scientific Leadership Group and MSBase Study Group. Mult Scler. (Apr 2017) 23(5):647-655. http://dx.doi.org/10.1177/1352458516662728

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.  Lizak, N., A. Lugaressi, R. Alroughani, J. Lechner-Scott, M. Slee, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, P. Grammond, R. Hupperts, F. Grand’Maison, P. Sola, E. Pucci, R. Bergamaschi, C. Oreja-Guevara, V. Van Pesch, C. Ramo, D. Spitaleri, G. Iuliano, C. Boz, F. Granella, J. Olascoaga, F. Verheul, C. Rozca, E. Cristiano, S. Flechter, S. Hodgkinson, M.P. Amato, N. Deri, V. Jokubaitis, T. Spelman, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Mar 2017) 88(3):196-203. http://dx.doi.org/10.1136/jnnp-2016-313976

Contribution of different relapse phenotypes to disability in multiple sclerosis. Stewart, T., T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, P. Sola, V. Shaygannejad, R. Hupperts, R. Alroughani, C. Oreja-Guevara, E. Pucci, C. Boz, J. Lechner-Scott, R. Bergamaschi, V. Van Pesch, G. Iuliano, C. Ramo, B. Taylor, M. Slee, D. Spitaleri, F. Granella, F. Verheul, P. McCombe, S. Hodgkinson, M. P. Amato, S. Vucic, O. Gray, E. Cristiano, M. Barnett, J. L. Sanchez- Menoyo, E. van Munster, M. L. Saladino, J. Olascoaga, J. Prevost, N. Deri, C. Shaw, B. Singhal, F. Moore, C. Rozsa, N. Shuey, O. Skibina, I. Kister, T. Petkovska-Boskova, R. Ampapa, A. Kermode, H. Butzkueven, V. Jokubaitis, T. Kalincik on behalf of the MSBase Study Group. Mult Scler. (Feb 2017) 23(2):266-276. http://dx.doi.org/10.1177/1352458516643392

2016

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Tao, C., S. Simpson Jr, I. van der Mei, L. Blizzard, E. Havrdova, D. Horakova, V. Shaygannejad, A. Lugaresi, G. Izquierdo, M. Trojano, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, R. Alroughani, M. Terzi, C. Oreja-Guevara, S.A. Sajedi, G. Iuliano, P. Sola, J. Lechner-Scott, V. Van Pesch, E. Pucci, R. Bergamaschi, M. Barnett, C. Ramo, B. Singhal, D. LA Spitaleri, M. Slee, F. Verheul, R. Fernández Bolaños, M.P. Amato, E. Cristiano, F. Granella, S. Hodgkinson, M. Fiol, O. Gray, P. McCombe, M.L. Saladino, J.L. Sanchez Menoyo, N. Shuey, S. Vucic, C. Shaw, N. Deri, W. Oleschko-Arruda, H. Butzkueven, T. Spelman, B.V. Taylor on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Dec 2016) 87(12):1343-1349. http://dx.doi.org/10.1136/jnnp-2016-314013

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Oct 2016) 87(10):1133-7. http://dx.doi.org/10.1136/jnnp-2016-313760

Defining secondary progressive multiple sclerosis. Lorscheider , J., K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J. Lechner-Scott, R. Bergamaschi, C. Oreja-Guevara, G. Iuliano, V. Van Pesch, F. Granella, C. Ramo-Tello, D. Spitaleri, T. Petersen, M. Slee, F. Verheul, R. Ampapa, MP. Amato, P. McCombe, S. Vucic, JL. Sanchez Menoyo, E. Cristiano, MH. Barnett, S. Hodgkinson, J. Olascoaga, ML. Saladino, O. Gray, C. Shaw, F. Moore, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. Brain. (Sep 2016) 139(Pt 9):2395-405. http://dx.doi.org/10.1093/brain/aww173

Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. Ann Neurol. (Jul 2016) 80(1):89-100. http://dx.doi.org/10.1002/ana.24682

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Jokubaitis, V.G., T. Spelman, T. Kalincik, J. Lorscheider, E. Havrdova, D. Horakova, P. Duquette, M. Girard, A. Prat, G. Izquierdo, P. Grammond, V. Van Pesch, E. Pucci, F. Grand’Maison, R. Hupperts, F. Granella, P. Sola, R. Bergamaschi, G. Iuliano, D. Spitaleri, C. Boz, S. Hodgkinson, J. Olascoaga, F. Verheul, D. Paolicelli, H. Butzkueven, A. Lugaresi and M. Trojano, for the MSBase Study Group. Neurol Clin Pract. (Apr 2016) 6(2):102-115. http://dx.doi.org/10.1212/CPJ.0000000000000227

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman, T., L. Mekhael, T. Burke, H. Butzkueven, S. Hodgkinson, E. Havrdova, D. Horakova, P. Duquette, G. Izquierdo, F. Grand’Maison, P. Grammond, M. Barnett, J. Lechner-Scott, R. Alroughani, M. Trojano, A. Lugaresi, F. Granella, E. Pucci and S. Vucic on behalf of the MSBase Study Group. Eur J Neurol. (Apr 2016) 23(4):729-736. http://dx.doi.org/10.1111/ene.12929

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Warrender-Sparkes, M., T. Spelman, G. Izquierdo, M. Trojano, A. Lugaresi, F. Grand’Maison, E. Havrdova, D. Horakova, C. Boz, C. Oreja-Guevara, R. Alroughani, G. Iuliano, P. Duquette, M. Girard, M. Terzi, R. Hupperts, P. Grammond, T. Petersen, R. Fernández Bolaños, M. Fiol, E. Pucci, J. Lechner-Scott, F. Verheul, E. Cristiano, V. Van Pesch, T. Petkovska-Boskova, F. Moore, I. Kister, R. Bergamaschi, M. L. Saladino, M. Slee, M. Barnett, M. P. Amato, C. Shaw, N. Shuey, C. Young, O. Gray, L. Kappos, H. Butzkeven, T. Kalincik and V. Jokubaitis, on behalf of the MSBase study group. Mult Scler. (Apr 2016) 22(4):520-532. http://dx.doi.org/10.1177/1352458515594041

2015

Defining reliable disability outcomes in multiple sclerosis. Kalincik, T., G. Cutter, T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Hupperts, C. Oreja-Guevara, C. Boz, E. Pucci, R. Bergamaschi, J. Lechner-Scott, R. Alroughani, V. Van Pesch, G. Iuliano, R. Fernández Bolaños, C. Ramo, M. Terzi, M. Slee, D. Spitaleri, F. Verheul, E. Cristiano, J. L. Sánchez-Menoyo, M. Fiol, O. Gray, J. A. Cabrera-Gomez, M. Barnett, H. Butzkueven, on behalf of the MSBase study group. Brain. (Nov 2015) 138 (Pt 11):3287-98. http://dx.doi.org/10.1093/brain/awv258

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik, T., V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, A. Lugaresi, C. Oreja-Guevara, R. Bergamaschi, R. Hupperts, F. Grand’Maison, E. Pucci, V. Van Pesch, C. Boz, G. Iuliano, R. Fernández Bolaños, S. Flechter, D. Spitaleri, E. Cristiano, F. Verheul, J. Lechner-Scott, M. P. Amato, J. A. Cabrera-Gomez, M. L. Saladino, M. Slee, F. Moore, O. Gray, M. Paine, M. Barnett, E. Havrdova, D. Horakova, T. Spelman, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. Mult Scler. (Aug 2015) 21(9):1159-71. http://dx.doi.org/10.1177/1352458514559865

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Rojas, J. I., L. Patrucco, M. Trojano, A. Lugresi, G. Izquierdo, H. Butzkueven, V. Jokubaitis, P. Duquette, M. Girard, F. Grand’Maison, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. Van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, R. Fernández Bolaños, D. Poehlau, M. L. Saladino, L. Den Braber-Moerland, N. Deri, W. Oleschko-Arruda, J. A. Cabrera-Gomez, M. Paine, N. Vella, I. Kister, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, E. A. Bacile Bacile, V. Santiago, E. Cristiano, on behalf of the MSBase study group. Mult Scler J Exp Transl Clin. (Aug 2015). http://dx.doi.org/10.1177/2055217315600193

Male Sex is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. Ribbons, K. A., P. McElduff, C. Boz, M. Trojano, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, R. Hupperts, P. Grammond, C. Oreja-Guevara, T. Petersen, R. Bergamaschi, G. Giuliani, M. Barnett, V. van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaños, M. L. Saladino, M. E. Rio, J. Cabrera-Gomez, H. Butzkueven, E. van Munster, L. Den Braber-Moerland, D. La Spitaleri, A. Lugaresi, V. Shaygannejad, O. Gray, N. Deri, R. Alroughani and J. Lechner-Scott. PLoS One. (Jun 2015) 10(6):e0122686. http://dx.doi.org/10.1371/journal.pone.0122686

BREMSO: a simple score to predict early the natural course of multiple sclerosis. Bergamaschi, R., C. Montomoli, G. Mallucci, A. Lugaresi, G. Izquierdo, F. Grand’Maison, P. Duquette, V. Shaygannejad, R. Alroughani, P. Grammond, C. Boz, G. Iuliano, C. Zwanikken, T. Petersen, J. Lechner-Scott, R. Hupperts, H. Butzkueven, E. Pucci, C. Oreja-Guevara, E. Cristiano, M. P. Pia Amato, E. Havrdova, R. Fernández Bolaños, T. Spelman and M. Trojano. Eur J Neurol. (Jun 2015) 22(6):981-9. http://dx.doi.org/10.1111/ene.12696

Predictors of disability worsening in clinically isolated syndrome. Jokubaitis, V. J., T. Spelman, T. Kalincik, G. Izquierdo, F. Grand’Maison, P. Duquette, M. Girard, A. Lugaresi, P. Grammond, R. Hupperts, J. Cabrera-Gomez, C. Oreja-Guevara, C. Boz, G. Giuliani, R. Fernández Bolaños, G. Iuliano, J. Lechner-Scott, F. Verheul, V. Van Pesch, T. Petkovska-Boskova, M. Fiol, F. Moore, E. Cristiano, R. Alroughani, R. Bergamaschi, M. Barnett, M. Slee, N. Vella, J. Herbert, C. Shaw, M. L. Saladino, M. P. Amato, D. Liew, D. Paolicelli, H. Butzkueven and M. Trojano, on behalf of the MSBasis Study Group. Ann Clin Transl Neurol. (May 2015) 2(5):479-91. http://dx.doi.org/10.1002/acn3.187

Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman, T., T. Kalincik, A. Zhang, F. Pellegrini, H. Wiendl, L. Kappos, L. Tsvetkova, S. Belachew, R. Hyde, F. Verheul, F. Grand-Maison, G. Izquierdo, P. Grammond, P. Duquette, A. Lugaresi, J. Lechner-Scott, C. Oreja-Guevara, R. Hupperts, T. Petersen, M. Barnett, M. Trojano and H. Butzkueven, on behalf of the MSBase Investigators and the TOP Investigators. Ann Clin Transl Neurol. (Apr 2015) 2(4):373-87. http://dx.doi.org/10.1002/acn3.180

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He, A., T. Spelman, V. Jokubaitis, E. Havrdova, D. Horakova, M. Trojano, A. Lugaresi, G. Izquierdo, P. Grammond, P. Duquette, M. Girard, E. Pucci, G. Iuliano, R. Alroughani, C. Oreja-Guevara, R. Fernández Bolaños, F. Grand’Maison, P. Sola, D. Spitaleri, F. Granella, M. Terzi, J. Lechner-Scott, V. Van Pesch, R. Hupperts, J. L. Sánchez-Menoyo, S. Hodgkinson, C. Rozsa, F. Verheul, H. Butzkueven, T. Kalincik; for the MSBase Study Group. JAMA Neurol. (Apr 2015) 72(4):405-13. http://dx.doi.org/10.1001/jamaneurol.2014.4147

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik, T., D. Horakova, T. Spelman, V. Jokubaitis, M. Trojano, A. Lugaresi, G. Izquierdo, C. Rozsa, P. Grammond, R. Alroughani, P. Duquette, M. Girard, E. Pucci, J. Lechner-Scott, M. Slee, R. Fernández Bolaños, F. Grand’Maison, R. Hupperts, F. Verheul, S. Hodgkinson, C. Oreja-Guevara, D. Spitaleri, M. Barnett, M. Terzi, R. Bergamaschi, P. McCombe, J. Sanchez-Menoyo, M. Simo, T. Csepany, G. Rum, C. Boz, E. Havrdova, H. Butzkueven; on behalf of the MSBase Study Group. Ann Neurol. (Mar 2015) 77(3):425-35. http://dx.doi.org/10.1002/ana.24339

2014

Seasonal variation of relapse rate in multiple sclerosis is latitude-dependent. Spelman, T., O. Gray, M. Trojano, T. Petersen, G. Izquierdo, A. Lugaresi, R. Hupperts, R. Bergamaschi, P. Duquette, P. Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja-Guevara, M. Barnett, F. Grand’Maison, M. E. Rio, J. Lechner-Scott, V. Van Pesch, R. Fernández Bolaños, S. Flechter, L. Den Braber-Moerland, G. Iuliano, M. P. Amato, M. Slee, E. Cristiano, M.L. Saladino, M. Paine, N. Vella, K. Kasa, N. Deri, J. Herbert, F. Moore, T. Petkovska-Boskova, R. Alroughani, A. Savino, C. Shaw, S. Vucic, V. Santiago, E. A. Bacile, E. Skromne, D. Poehlau, J. A. Cabrera-Gomez, R. Lucas and H. Butzkueven. Ann Neurol. (Dec 2014) 76(6):880-90. http://dx.doi.org/10.1002/ana.24287

Risk of relapse phenotype recurrence in multiple sclerosis. Kalincik, T., K. Buzzard, V. G. Jokubaitis, M. Trojano, P. Duquette, I. Guillermo, M. Girard, A. Lugaresi, P. Grammond, F. Grand’Maison, C. Oreja-Guevara, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, G. Iuliano, J. Lechner-Scott, M. Barnett, R. Bergamaschi, V. Van Pesch, M. P. Amato, E. van Munster, R. Fernandez-Bolanos, F. Verheul, M. Fiol, E. Cristiano, M. Slee, M. E. Rio, D. L. A. Spitaleri, R. Alroughani, O. Gray, M. L. Saladino, S. Flechter, J. Herbert, J. A. Cabrera- Gomez, N. Vella, M. Paine, C. Shaw, F. Moore, S. Vucic, A. Savino, B. Singhal, T. Pekovska-Boskova, J. Parratt, C-A. Sirbu, C. Rozsa, D. Liew, H. Butzkueven, on behalf of the MSBase study group. Mult Scler. (Oct 2014) 20(11):1511-22. http://dx.doi.org/10.1177/1352458514528762

Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Hughes, S. E., T. Spelman, O. M. Gray, C. Boz, M. Trojano, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. van Pesch, M. P. Amato, G. Iuliano, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolanos, D. Poehlau, M. L. Saladino, N. Deri, J. Cabrera-Gomez, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, G. McDonnell, S. A. Hawkins, F. Kee, H. Butzkueven on behalf of the MSBase study group. Mult Scler. (May 2014) 20(6):739-46. http://dx.doi.org/10.1177/1352458513507816

Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis, V. G., V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, R. Alroughani, J. Lechner-Scott, A. Lugaresi, P. Duquette, M. Girard, M. Barnett, F. Grand’Maison, M. Trojano, M. Slee, G. Giuliani, C. Shaw, C. Boz, D. L. A. Spitaleri, F. Verheul, J. Haartsen, D. Liew, H. Butzkueven on behalf of the MSBase study group. Neurology. (Apr 2014) 82(14):1204-11. http://dx.doi.org/10.1212/WNL.0000000000000283

2013

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Kalincik, T., V. Vivek, V. Jokubaitis, J. Lechner-Scott, M. Trojano, G. Izquierdo, A. Lugaresi, F. Grand’Maison, R. Hupperts, C. Oreja-Guevara, R. Bergamaschi, G. Iuliano, R. Alroughani, V. Van Pesch, M. P. Amato, M. Slee, F. Verheul, R. Fernandez-Bolanos, M. Fiol, D. L. A. Spitaleri, E. Cristiano, O. Gray, J. A. Cabrera-Gomez, V. Shaygannejad, J. Herbert, S. Vucic, M, Needham, T. Petkovska-Boskova, C-A. Sirbu, P. Duquette, M. Girard, P. Grammond, C. Boz, G. Giuliani, M. E. Rio, M. Barnett, S. Flechter, F. Moore, B. Singhal, E. A. Bacile, M. L. Saladino, C. Shaw, E. Skromne, D. Poehlau, N. Vella, T. Spelman, D. Liew, T. J. Kilpatrick, H. Butzkueven on behalf of the MSBase Study Group. Brain. (Dec 2013) 136(Pt 12):3609-17. http://dx.doi.org/10.1093/brain/awt281

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. Kalincik, T., T. Spelman, M. Trojano, P. Duquette, G. Izquierdo, P. Grammond, A. Lugaresi, R. Hupperts, E. Cristiano, V. Van Pesch, F. Grand'Maison, D. La Spitaleri, M. E. Rio, S. Flechter, C. Oreja-Guevara, G. Giuliani, A. Savino, M. P. Amato, T. Petersen, R. Fernandez-Bolanos, R. Bergamaschi, G. Iuliano, C. Boz, J. Lechner-Scott, N. Deri, O. Gray, F. Verheul, M. Fiol, M. Barnett, E. van Munster, V. Santiago, F. Moore, M. Slee, M. L. Saladino, J. Alroughani, C. Shaw, K. Kasa, T. Petkovska- Boskova, L. den Braber-Moerland, J. Chapman, E. Skromne, J. Herbert, D. Poehlau, M. Needham, E. A. Bacile Bacile, W. O. Arruda, M. Paine, B. Singhal, S. Vucic, J. A. Cabrera-Gomez, H. Butzkueven on behalf of the MSBase Study Group. PLoS One. (May 2013) 8(5):e63480. http://dx.doi.org/10.1371/journal.pone.0063480

Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. Iuliano, G., C. Boz, E. Cristiano, P. Duquette, A. Lugaresi, C. Oreja-Guevara and V. Van Pesch. J Neurol. (May 2013) 260(5): 1258-62. http://dx.doi.org/10.1007/s00415-012-6785-y

Fluctuations of MS Births and UV-light exposure. Verheul, F., J. Smolders, M. Trojano, V. Lepore, C. Zwanikken, M. P. Amato, F. Grand'maison, H. Butzkueven, M. Marrosu, P. Duquette, G. Comi, G. Izquierdo, P. Grammond, G. Lus, T. Petersen, R. Bergamaschi, G. Giuliani, C. Boz, G. Coniglio, V. Van Pesch, J. Lechner-Scott, P. Cavalla, F. Granella, C. Avolio, M. Fiol, D. Poehlau, M. L. Saladino, P. Gallo, N. Deri, W. Oleschko Arruda, M. Paine, M. Ferro, M. Barnett, J. A. Cabrera-Gomez, M. Slee, F. Moore, C. Shaw, T. Petkovska-Boskova, M. Rutherford, O. Engelsen, J. Damoiseaux and R. Hupperts. Acta Neurol Scand. (May 2013) 127(5):301-8. http://dx.doi.org/10.1111/ane.12007

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis, V. G., T. Spelman, J. Lechner-Scott, M. Barnett, C. Shaw, S. Vucic, S. Liew, H. Butzkueven, M. Slee on behalf of the Australian MSBase Study Group. PLoS One. (Mar 2013) 8(3):e59694. http://dx.doi.org/10.1371/journal.pone.0059694

2012

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. Trojano, M., G. Lucchese, G. Graziano, B. V. Taylor, S. Simpson, Jr., V. Lepore, F. Grand'Maison, P. Duquette, G. Izquierdo, P. Grammond, M. P. Amato, R. Bergamaschi, G. Giuliani, C. Boz, R. Hupperts, V. Van Pesch, J. Lechner-Scott, E. Cristiano, M. Fiol, C. Oreja-Guevara, M. L. Saladino, F. Verheul, M. Slee, D. Paolicelli, C. Tortorella, M. D'Onghia, P. Iaffaldano, V. Direnzo, H. Butzkueven on behalf of the MSBase Study Group, the New Zealand MS Prevalence Study Group. PLoS One. (Oct 2012) 7(10):e48078. http://dx.doi.org/10.1371/journal.pone.0048078

Increasing age at disability milestones among MS patients in the MSBase registry. Kister, I., E. Chamot, G. Cutter, T. E. Bacon, V. G. Jokubaitis, S. E. Hughes, O. M. Gray, M. Trojano, G. Izquierdo, F. Grand'Maison, P. Duquette, A. Lugaresi, P. Grammond, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, C. Oreja- Guevara, G. Iuliano, J. Lechner-Scott, R. Bergamaschi, M. E. Rio, F. Verheul, M. Fiol, V. Van Pesch, M. Slee, H. Butzkueven, J. Herbert and MSBase Investigators. J Neurol Sci. (Jul 2012) 318(1-2):94-9. http://dx.doi.org/10.1016/j.jns.2012.03.017

The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Lechner-Scott, J., B. Spencer, T. de Malmanche, J. Attia, M. Fitzgerald, M. Trojano, F. Grand'Maison, J. A. C. Gomez, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, C. Boz, G. Giuliani, V. Van Pesch, G. Iuliano, M. Fiol, E. Cristiano, F. Verheul, M. L. Saladino, M. Slee, M. Barnett, N. Deri, S. Flechter, N. Vella, C. Shaw, J. Herbert, F. Moore, T. Petkovska-Boskova, V. Jokubaitis, H. Butzkueven for the MSBase study group. Mult Scler. (Jul 2012) 18(7):974-82. http://dx.doi.org/10.1177/1352458511431729

Country, Sex, Edss Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. Meyniel, C., T. Spelman, V. G. Jokubaitis, M. Trojano, G. Izquierdo, F. Grand'Maison, C. Oreja-Guevara, C. Boz, A. Lugaresi, M. Girard, P. Grammond, G. Iuliano, M. Fiol, J. A. Cabrera-Gomez, R. Fernández Bolaños, G. Giuliani, J. Lechner-Scott, E. Cristiano, J. Herbert, T. Petkovska-Boskova, R. Bergamaschi, V. Van Pesch, F. Moore, N. Vella, M. Slee, V. Santiago, M. Barnett, E. Havrdova, C. Young, C-A. Sirbu, M. Tanner, M. Rutherford, H. Butzkueven, on behalf of the MSBasis Study Group. PLoS One. (Jun 2012) 7(6):e38661. http://dx.doi.org/10.1371/journal.pone.0038661

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase registry. Hughes, S., T. Spelman, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand'Maison, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, R. Bergamaschi, G. Giuliani, M. E. Rio, J. Lechner-Scott, V. van Pesch, G. Iuliano, M. Fiol, F. Verheul, M. Barnett, M. Slee, J. Herbert, I. Kister, N. Vella, F. Moore, T. Petkovska-Boskova, V. Shaygannejad, V. Jokubaitis, G. McDonnell, S. Hawkins, F. Kee, O. Gray, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Mar 2012) 83(3):305-10. http://dx.doi.org/10.1136/jnnp-2011-301051

2006

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Butzkueven, H., J. Chapman, E. Cristiano, F. Grand'Maison, M. Hoffmann, G. Izquierdo, D. Jolley, L. Kappos, T. Leist, D. Pöhlau, V. Rivera, M. Trojano, F. Verheul and J-P. Malkowski. Mult Scler. (Dec 2006) 12(6):769-74. http://dx.doi.org/10.1177/1352458506070775